摘要
目的探讨替米沙坦联合瑞舒伐他汀对老年高血压患者脑白质损害的影响。方法选择2011年10月~2012年10月济南地区老年轻、中度原发性高血压患者329例,随机分为对照组167例及联合组162例。2组均给予替米沙坦40mg/d降压治疗,联合组此基础上加用瑞舒伐他汀钙10mg/d。分别在基线第3年和第5年采用头颅MRI评估脑白质高信号(WMH)、脑室周围白质高信号(PWMH)及深部白质高信号(DWMH)。结果与基线比较,对照组第3年、第5年总WMH、PWMH及DWMH显著增高[(9.34±2.28)ml,(12.19±2.61)ml vs(6.21±2.19)ml,P<0.05;(6.70±2.01)ml,(8.63±2.21)ml vs(4.54±1.92)ml,P<0.05;(2.63±0.80)ml,(3.56±0.94)ml vs(1.66±0.73)ml,P<0.05];联合组第3年、第5年总WMH、PWMH及DWMH显著增高[(8.65±1.78)ml,(10.25±2.02)ml vs(6.42±1.90)ml,P<0.05;(6.27±1.64)ml,(7.38±1.78)ml vs(4.71±1.72)ml,P<0.05;(2.37±0.70)ml,(2.87±0.80)ml vs(1.71±0.65)ml,P<0.05]。联合组第3年、第5年增长率变化趋势明显低于对照组(P<0.05)。结论替米沙坦联合瑞舒伐他汀在平稳降压、有效调脂的同时,可延缓脑白质损害的进展。
Objective To study the effect of telmisartan combined with rosuvastatin on white matter lesion （WML） in elderly hypertensive patients. Metheds Three hundred and twenty-nine elderly patients with mild-moderate essential hypertension （EH） were divided into control group （n = 167） and combined treatment group （n= 162）. The patients in control group were treated with telmisartan （40 mg/d） and those in combined treatment group were treated with telmisartan plus rosuvastatin （10 rag/d）. Their white matter hyperintensivity （WMH）, periventricular white matter hyperintensity （PWMH）, and deep white matter hyperintensity （DWMH） were measured by head MRI. Results The total WMH,PWMH and DWMH were significantly higher in two groups in the third and fifth years than at the baseline （P〈0. 05）. The growth rate of total WMH, PWMH and DWMH was significantly lower in combined treatment group than in control group in the third and fifth years （P〈0.05）. Conclusion Telmisartan combined with rosuvastatin plays an important role in stablizing blood pressure,regulating blood lipids,and delaying WML.
出处
《中华老年心脑血管病杂志》
CAS
北大核心
2018年第2期145-148,共4页
Chinese Journal of Geriatric Heart,Brain and Vessel Diseases
基金
国家自然科学基金(81670432
81470489)
山东省自然科学基金(ZR2016HM82
ZR2014HM098)
山东省医药卫生科技发展计划(2015WS0187
2016WS0527)
山东省中医药科技发展计划(2015-324)
山东省重点研发计划(2017GSF218060)
关键词
高血压
磁共振成像
血脂异常
降血脂药
抗高血压药
脑白质疏松症
hypertension
magnetic resonance imaging
dyslipidemias
antilipemic agents
antihypertensive agents
leukoaraiosis
